Titan Pharmaceuticals, Inc. (TTNP): Price and Financial Metrics
GET POWR RATINGS... FREE!
TTNP POWR Grades
- Growth is the dimension where TTNP ranks best; there it ranks ahead of 57.57% of US stocks.
- The strongest trend for TTNP is in Growth, which has been heading up over the past 159 days.
- TTNP's current lowest rank is in the Quality metric (where it is better than 3.93% of US stocks).
TTNP Stock Summary
- With a year-over-year growth in debt of -81.78%, Titan Pharmaceuticals Inc's debt growth rate surpasses merely 3.08% of about US stocks.
- The volatility of Titan Pharmaceuticals Inc's share price is greater than that of 98.49% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TTNP comes in at -74.81% -- higher than that of merely 3.24% of stocks in our set.
- Stocks that are quantitatively similar to TTNP, based on their financial statements, market capitalization, and price volatility, are ANTE, ESMC, VERO, NTZ, and NSEC.
- Visit TTNP's SEC page to see the company's official filings. To visit the company's web site, go to www.titanpharm.com.
TTNP Stock Price Chart Interactive Chart >
TTNP Price/Volume Stats
|Current price||$2.46||52-week high||$14.06|
|Prev. close||$2.43||52-week low||$2.15|
|Day high||$2.46||Avg. volume||1,188,188|
|50-day MA||$2.67||Dividend yield||N/A|
|200-day MA||$4.15||Market Cap||24.27M|
Titan Pharmaceuticals, Inc. (TTNP) Company Bio
Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company was founded in 1992 and is based in South San Francisco, California.
TTNP Latest News Stream
|Loading, please wait...|
TTNP Latest Social Stream
View Full TTNP Social Stream
Latest TTNP News From Around the Web
Below are the latest news stories about Titan Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTNP as an investment opportunity.
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ: TXG ) Affimed N.V. (NASDAQ: AFMD ) Bio-Techne Corporation (NASDAQ: TECH ) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ: XNCR ) BioNTech SE (NASDAQ: BNTX ) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson & Johnson (NYSE: JNJ ) setback Globus Medical, Inc. (NYSE: GMED ) Medpace Holdings, Inc. (NASDAQ: MEDP ) Medtronic plc (NYSE: MDT ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natus Medical Incorporated (NASDAQ: NTUS ) NuVasive, Inc. (NASDAQ: NUVA ) PLx Pharma Inc. (NASDAQ: PLXP ) PPD, Inc. (NASDAQ: PPD ) - moved on rumors of a potential buyo...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) is set to begin a new phase, according to Maxim Group, after undergoing several changes in strategy, management, capital structure and financing through 2020 and into 2021. The Titan Pharmaceuticals Analyst: Jason McCarthy upgraded the rating for Titan Pharmaceuticals from Hold to Buy, while establishing a price target of $11. The Titan Pharmaceuticals Thesis: Given the … Full story available on Benzinga.com
Accepted 2021-02-08 00:15:26 Documents Thank you for supporting Stocks News Feed. As an Amazon affiliate, we earn from qualifying purchases. 1 Effectiveness Date 2021-02-05 Registration Form S-1 Document Format Files Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990… Read More »EFFECT – TITAN PHARMACEUTICALS INC (0000910267) (Filer)
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed…
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a…
TTNP Price Returns
Continue Researching TTNPHere are a few links from around the web to help you further your research on Titan Pharmaceuticals Inc's stock as an investment opportunity:
Titan Pharmaceuticals Inc (TTNP) Stock Price | Nasdaq
Titan Pharmaceuticals Inc (TTNP) Stock Quote, History and News - Yahoo Finance
Titan Pharmaceuticals Inc (TTNP) Stock Price and Basic Information | MarketWatch